Safety and Efficacy of Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors vs. Erythropoietin-Stimulating Agents in Treating Anemia in Renal Patients (With or Without Dialysis): A Meta-Analysis and Systematic Review

Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) are a novel group of drugs used to treat renal anemia, but their benefits vary among different trials. Our meta-analysis aims to assess the safety and efficacy of HIF-PHI versus erythropoiesis-stimulating agents (ESA) in managi...

Descripción completa

Detalles Bibliográficos
Autores principales: Damarlapally, Nanush, Thimmappa, Vijaylaxmi, Irfan, Hamza, Sikandari, Muhammad, Madhu, Krupa, Desai, Aayushi, Pavani, Peddi, Zakir, Syeda, Gupta, Manvi, Khosa, Maha Mushtaq, Kotak, Sohny, Varrassi, Giustino, Khatri, Mahima, Kumar, Satesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659060/
https://www.ncbi.nlm.nih.gov/pubmed/38021836
http://dx.doi.org/10.7759/cureus.47430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659060/
https://www.ncbi.nlm.nih.gov/pubmed/38021836
http://dx.doi.org/10.7759/cureus.47430

Ejemplares similares